吉非替尼在晚期胰腺癌治疗中的临床价值  

The clinical value of Gefitinib in the treatment of advanced pancreatic cancer

作　　者：范国宇[1] 刘伟[1] 

机构地区：[1]吉林市中心医院肿瘤三科,132001

出　　处：《中国实用医药》2013年第5期66-67,共2页China Practical Medicine

摘　　要：目的观察吉非替尼(Iressa)治疗晚期胰腺癌的疗效、临床受益反应和毒性反应。方法 16例晚期胰腺癌患者,均有组织病理学或细胞学诊断及可评价的客观指标。采用吉非替尼(Iressa)口服500mg/d。结果 16例患者中,有14例可以评价疗效,其中获得CR1例,PR4例,SD4例,PD5例。总有效率为35.71%,稳定率为28.57%,临床受益反应率为64.29%。结论吉非替尼可以用于治疗晚期胰腺癌患者,副反应可以耐受。Objective To evaluate the efficacy and toxicity of gefitinib in treatment of patients with ad- vanced pancreatic cancer. Methods 16 patients with advanced pancreatic cancer. Gefitinib was administered orally at 500 mg, once a day. Results Of the 16 patients, 14 patients can be evaluated, 1 got complete re- sponse （CR）, g partial response（PR）, 4 stable disease（SD） , and 5 progress of disease（PD）. The total re- sponse rate was 35.71%, Stable rate was 28.57% and disease control rate was 64. 29%. Conclusion Ge- fitinib is effective and tolerable for the patients with advanced pancreatic cancer.

关 键 词：吉非替尼 晚期胰腺癌 治疗 临床价值 

分 类 号：R735.9[医药卫生—肿瘤]